Taysha Gene Therapies, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Taysha Gene Therapies, Inc. (TSHA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $556.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- Taysha Gene Therapies, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $271.00K, a 12.01% decline year-over-year.
- Taysha Gene Therapies, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $285.00K, a 15.93% decline year-over-year.
- Taysha Gene Therapies, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $400.00K, a 32.89% increase year-over-year.
- Taysha Gene Therapies, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $312.00K, a 5.05% increase year-over-year.
- Taysha Gene Therapies, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.36M, a 11.67% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.22M, a 2.96% increase from fiscal 2023.
- Taysha Gene Therapies, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.18M, a 10.11% decline from fiscal 2022.
- Taysha Gene Therapies, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.31M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $271.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $556.00K 10-Q · filed 2026-08-11 | $956.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.27M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $285.00K 10-Q · filed 2026-05-06 | $685.00K derived: sum of 2 quarters · filed 2026-05-06 | $997.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.30M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $712.00K derived: sum of 2 quarters · filed 2026-03-19 | $1.02M derived: sum of 3 quarters · filed 2026-08-11 | $1.36M 10-K · filed 2026-03-19 |
| 2025-09-30 | $312.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $620.00K derived: sum of 2 quarters · filed 2026-08-11 | $959.00K 10-Q · filed 2025-11-04 | $1.26M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $308.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $647.00K 10-Q · filed 2026-08-11 | $948.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.25M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $339.00K 10-Q · filed 2026-05-06 | $640.00K derived: sum of 2 quarters · filed 2026-05-06 | $937.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.23M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $301.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $598.00K derived: sum of 2 quarters · filed 2026-03-19 | $892.00K derived: sum of 3 quarters · filed 2026-03-19 | $1.22M 10-K · filed 2026-03-19 |
| 2024-09-30 | $297.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $591.00K derived: sum of 2 quarters · filed 2025-11-04 | $916.00K 10-Q · filed 2025-11-04 | $1.19M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $294.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $619.00K 10-Q · filed 2025-08-12 | $893.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.20M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $325.00K 10-Q · filed 2025-05-15 | $599.00K derived: sum of 2 quarters · filed 2025-05-15 | $904.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.21M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $274.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $579.00K derived: sum of 2 quarters · filed 2025-02-26 | $882.00K derived: sum of 3 quarters · filed 2025-02-26 | $1.18M 10-K · filed 2025-02-26 |
| 2023-09-30 | $305.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $608.00K derived: sum of 2 quarters · filed 2024-11-13 | $908.00K 10-Q · filed 2024-11-13 | $1.19M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $303.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $603.00K 10-Q · filed 2024-08-12 | $887.00K derived: sum of 3 quarters · filed 2024-08-12 | $1.27M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $300.00K 10-Q · filed 2024-05-14 | $584.00K derived: sum of 2 quarters · filed 2024-05-14 | $969.00K derived: sum of 3 quarters · filed 2024-05-14 | $1.31M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $284.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $669.00K derived: sum of 2 quarters · filed 2024-03-19 | $1.01M derived: sum of 3 quarters · filed 2024-03-19 | $1.31M 10-K · filed 2024-03-19 |
| 2022-09-30 | $385.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $722.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.03M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $337.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $646.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $309.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |